Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.

@article{Menzies2004TreatmentCA,
  title={Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.},
  author={D. Menzies and M. Dion and B. Rabinovitch and S. Mannix and P. Brassard and K. Schwartzman},
  journal={American journal of respiratory and critical care medicine},
  year={2004},
  volume={170 4},
  pages={
          445-9
        }
}
There is little published information regarding treatment completion, safety, and efficacy of rifampin administered daily for 4 months-a recommended alternative to 9 months of isoniazid for therapy of latent tuberculosis infection. In an open-label randomized trial at a university-affiliated respiratory hospital, consenting patients whose treating physician had recommended therapy for latent tuberculosis infection were randomized to daily self-administered rifampin for 4 months or daily self… Expand
148 Citations
Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection
  • 189
  • PDF
Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
  • 152
  • Highly Influenced
  • PDF
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
  • 130
  • PDF
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
  • 8
Safety and Side Effects of Rifampin versus Isoniazid in Children
  • 51
  • PDF
Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail Inmates
  • M. White, J. Tulsky, +4 authors L. Kawamura
  • Medicine
  • Journal of correctional health care : the official journal of the National Commission on Correctional Health Care
  • 2012
  • 19
  • Highly Influenced
4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
  • P. Ziakas, E. Mylonakis
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
  • 93
  • Highly Influenced
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
  • 81
Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.
  • 128
Use of isoniazid for latent tuberculosis infection in a public health clinic.
  • P. Lobue, K. Moser
  • Medicine
  • American journal of respiratory and critical care medicine
  • 2003
  • 217
Rifampin preventive therapy for tuberculosis in Boston's homeless.
  • 86
Factors associated with compliance in treatment of tuberculosis.
  • 85
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
  • 86
...
1
2
3
4
...